Overview

Topical Rapamycin for Fibrofolliculomas

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones. Secondary we evaluate rapamycin safety, formula acceptance and patient satisfaction.
Phase:
Phase 3
Details
Lead Sponsor:
Maastricht University Medical Center
Collaborator:
Myrovlytis Trust
Treatments:
Everolimus
Sirolimus